Información: Estado Tipo de Participantes Rangos de Edad

Identificador 2022-500461-28-06 (CTIS)
05/09/2022
Estado No iniciado
REGISTRO ESPAÑOL DE ENSAYOS CLINICOS Página 1 de 11
A Study of Abemaciclib (LY2835219) with Abiraterone in Men with Prostate Cancer that has
Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment
(Metastatic Hormone-Sensitive Prostate Cancer) (CYCLONE 3).
Estado Tipo de Participantes Rangos de Edad

No iniciado No aportado Mayores de 64 , Adultos
Género Fases Participantes esperados

Hombres Fase III 912
Resultados Bajo nivel intervención Enfermedad rara

Sin resultados No No
Cobertura geográfica Ámbitos del ensayo Tipo de promotor

Multicéntrico internacional tratamiento, seguridad, eficacia, Comercial
farmacocinética, farmacogenómica
Información
Identificador Cod. Protocolo

2022-500461-28-06 (CTIS) I3Y-MC-JPEG
Área terapéutica
Enfermedades [C] - Neoplasma [C04]
Enfermedad investigada
High-Risk Metastatic Hormone-Sensitive Prostate Cancer
Título Científico
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination with
Abiraterone plus Prednisone in Men with High-Risk Metastatic Hormone-Sensitive Prostate Cancer
05/09/2022
Estado No iniciado
Justificación
In line with the EMA Appendix on disclosure rules to the ¿Functional specifications for the EU portal and EU
database to be audited- EMA/42176/2014¿, the trial meets the definition of category 2 trial since it is a Phase III trial
assessing a new indication for an authorised IMP to to confirm safety and efficacy
Objetivo Principal
To determine whether adding abemaciclib to abiraterone plus prednisone improves radiographic progression-free
survival (rPFS).
Variables de Evaluación Primaria

Radiographic progression-free survival (rPFS) assessed by the investigator.
Momentos temporales de evaluación primaria

No aportado
Objetivo Secundario
To evaluate improvements in other clinically relevant efficacy endpoints with the addition of abemaciclib to
abiraterone plus prednisone|To characterize the safety of adding abemaciclib to abiraterone plus prednisone|To
characterize the PK of abemaciclib when administered in combination with abiraterone.|To assess patient-reported
pain and HRQoL
Variables de Evaluación Secundaria

rPFS by blinded, independent, central review (BICR)|Clinical PFS (cPFS)|Castration-resistant prostate cancer
(CRPC)-free survival|Time to symptomatic progression|Time to PSA progression|Time to initiation of new anticancer
therapy|Overall survival (OS).|The safety endpoints evaluated will include, but are not limited to, the following: AEs,
TEAEs, SAEs, clinical laboratory tests, ECGs, vital signs, and physical examinations.|Concentrations of
abemaciclib.|Time to pain progression|Time to deterioration in HRQoL measured by the FACT-P (Physical Well-
Being and PCS scores) and EQ-5D-5L.
Momentos temporales de evaluación secundaria

No aportado
Criterios de Inclusión
05/09/2022
Estado No iniciado
Prostate cancer that has spread to other parts of the body and is expected to respond to hormone treatments
designed to lower testosterone (metastatic hormone-sensitive prostate cancer)|Cancer that has spread to the bones
significantly and/or to the viscera, which are the soft internal organs of the body (for example, the lungs, liver, and the
organs of the digestive system).|Adequate organ function
Criterios de Exclusión
Received prior treatment with abemaciclib or other drugs that work in the same way|Received previous treatment(s)
for metastatic cancer except for up to 3 months of androgen deprivation therapy (ADT) or up to 6 courses of
chemotherapy with ADT|Serious or uncontrolled medical conditions such as certain cardiovascular disorders, active
or chronic liver disease, uncontrolled hypertension, active systemic infections or currently treated for cancer other
than prostate|Prostate cancer that has spread to the central nervous system that is not treated and stable
Calendario
(Última actualización: 05/09/2022)
Autorización Inicio de Inclusión Interrumpido Reiniciado

Ensayo Primer Paciente
05/09/2022 No aportado No aportado
No aportado No aportado
Fin de Fin prematuro Fin prematuro Fin del ensayo Fin del ensayo
reclutamiento (España) (Global) en España global
No aportado No aportado No aportado No aportado No aportado

05/09/2022
Estado No iniciado
Promotor
Eli Lilly Cork Limited Ireland

Island House Eastgate RoadEastgate Business ParkLittle Island
Contact Person
Katie Wray
003530214232400
wray_katie@lilly.com
Monetary support: N/A

05/09/2022
Estado No iniciado
Centros
- -
N/A - N/A -
- -
No iniciado (--/--/----)
L'hospitalet De Llobregat Badajoz
- -
Oncology - Oncology -
- -
- -
- -
- -
- -
- -
N/A - N/A -
- -
Sevilla Madrid
- -
- -
- -
- -
- -
- -
- -
N/A - N/A -
- -
Madrid Valencia
- -
- -
- -
- -
- -
- -
-
N/A -
-
Madrid
-
Oncology -
-
-
-
-
-
05/09/2022
Estado No iniciado
Medicamentos
ABIRATERONE ACETATE PREDNISONE

FILM-COATED TABLET TABLET
ORAL ORAL
- -
Principios Activos: N/A Principios Activos: N/A
Experimental Experimental
Verzenios 50 mg film-coated tablets Placebo to Match LY2835219 50-mg Tablets

FILM-COATED TABLET N/A
ORAL
Código ATC: L01EF03 - ABEMACICLIB

-
Principios Activos: N/A
Experimental
Huérfano Experimental
PREDNISOLONE
TABLET
ORAL
-
Experimental
Sin resultados
Identifier 2022-500461-28-06 (CTIS)
05/09/2022
State Not initiated
REGISTRO ESPAÑOL DE ENSAYOS CLINICOS Page 7 of 11
A Study of Abemaciclib (LY2835219) with Abiraterone in Men with Prostate Cancer that has
Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment
(Metastatic Hormone-Sensitive Prostate Cancer) (CYCLONE 3).
State Type of participants Age Ranges

Not initiated Not provided Older than 64 , Adults
Gender Phases Expected Participants

Men Phase III 912
Results Low level of intervention Rare disease

No results No No
Geographic coverage Areas of the study Sponsor type

International multicenter treatment, safety, effectiveness, Commercial
pharmacokinetics, pharmacogenomics
Information
Identifier Protocol Code

2022-500461-28-06 (CTIS) I3Y-MC-JPEG
Therapeutic area
Diseases [C] - Neoplasms [C04]
Investigated Disease
High-Risk Metastatic Hormone-Sensitive Prostate Cancer
Scientific Title
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination with
Abiraterone plus Prednisone in Men with High-Risk Metastatic Hormone-Sensitive Prostate Cancer
05/09/2022
State Not initiated
Rationale
In line with the EMA Appendix on disclosure rules to the ¿Functional specifications for the EU portal and EU
database to be audited- EMA/42176/2014¿, the trial meets the definition of category 2 trial since it is a Phase III trial
assessing a new indication for an authorised IMP to to confirm safety and efficacy
Main Objective
To determine whether adding abemaciclib to abiraterone plus prednisone improves radiographic progression-free
survival (rPFS).
Primary Endpoints
Radiographic progression-free survival (rPFS) assessed by the investigator.
Temporary moments of secondary assessment

Not provided
Secondary Objective
To evaluate improvements in other clinically relevant efficacy endpoints with the addition of abemaciclib to
abiraterone plus prednisone|To characterize the safety of adding abemaciclib to abiraterone plus prednisone|To
characterize the PK of abemaciclib when administered in combination with abiraterone.|To assess patient-reported
pain and HRQoL
Secondary Endpoints
rPFS by blinded, independent, central review (BICR)|Clinical PFS (cPFS)|Castration-resistant prostate cancer
(CRPC)-free survival|Time to symptomatic progression|Time to PSA progression|Time to initiation of new anticancer
therapy|Overall survival (OS).|The safety endpoints evaluated will include, but are not limited to, the following: AEs,
TEAEs, SAEs, clinical laboratory tests, ECGs, vital signs, and physical examinations.|Concentrations of
abemaciclib.|Time to pain progression|Time to deterioration in HRQoL measured by the FACT-P (Physical Well-
Being and PCS scores) and EQ-5D-5L.
Temporary moments of secondary assessment

Not provided
Inclusion criteria
05/09/2022
State Not initiated
Prostate cancer that has spread to other parts of the body and is expected to respond to hormone treatments
designed to lower testosterone (metastatic hormone-sensitive prostate cancer)|Cancer that has spread to the bones
significantly and/or to the viscera, which are the soft internal organs of the body (for example, the lungs, liver, and the
organs of the digestive system).|Adequate organ function
Exclusion criteria
Received prior treatment with abemaciclib or other drugs that work in the same way|Received previous treatment(s)
for metastatic cancer except for up to 3 months of androgen deprivation therapy (ADT) or up to 6 courses of
chemotherapy with ADT|Serious or uncontrolled medical conditions such as certain cardiovascular disorders, active
or chronic liver disease, uncontrolled hypertension, active systemic infections or currently treated for cancer other
than prostate|Prostate cancer that has spread to the central nervous system that is not treated and stable
Calendar
(Last Update: 05/09/2022)
Authorization Start of Trial First patient Halted Restarted

inclusion
05/09/2022 Not aported Not aported Not aported
Not aported
End of Premature end Premature End Trial end Trial end

recruitment (Spain) (Global) (Spain) (Global)
Not aported Not aported Not aported Not aported Not aported
Sponsor
Eli Lilly Cork Limited Ireland

Island House Eastgate RoadEastgate Business ParkLittle Island
Contact Person
Katie Wray
003530214232400
wray_katie@lilly.com
Monetary support: N/A

05/09/2022
State Not initiated
Sites
- -
N/A - N/A -
not initialized (--/--/----)

- -
L'hospitalet De Llobregat Badajoz
- -
- -
- -
- -
- -
- -
- -
N/A - N/A -
- -
Sevilla Madrid
- -
- -
- -
- -
- -
- -
- -
N/A - N/A -
- -
Madrid Valencia
- -
- -
- -
- -
- -
- -
-
N/A -
-
Madrid
-
Oncology -
-
-
-
-
-
05/09/2022
State Not initiated
Medication
ABIRATERONE ACETATE PREDNISONE

FILM-COATED TABLET TABLET
ORAL ORAL
Active Principles: N/A

-
Experimental Active Principles: N/A
Experimental
Verzenios 50 mg film-coated tablets Placebo to Match LY2835219 50-mg Tablets

FILM-COATED TABLET N/A
ORAL
ATC code: L01EF03 - ABEMACICLIB

-
Experimental
Orphan Experimental
PREDNISOLONE
TABLET
ORAL
-
Experimental
No results

Información: Estado Tipo de Participantes Rangos de Edad

Uploaded by

Document Information

Original Description:

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Información: Estado Tipo de Participantes Rangos de Edad

Uploaded by

Copyright:

Available Formats

Identificador 2022-500461-28-06 (CTIS)

Estado Tipo de Participantes Rangos de Edad

Género Fases Participantes esperados

Resultados Bajo nivel intervención Enfermedad rara

Cobertura geográfica Ámbitos del ensayo Tipo de promotor

Identificador Cod. Protocolo

Variables de Evaluación Primaria

Momentos temporales de evaluación primaria

Variables de Evaluación Secundaria

Momentos temporales de evaluación secundaria

Autorización Inicio de Inclusión Interrumpido Reiniciado

No aportado No aportado No aportado No aportado No aportado

Eli Lilly Cork Limited Ireland

Monetary support: N/A

ABIRATERONE ACETATE PREDNISONE

Verzenios 50 mg film-coated tablets Placebo to Match LY2835219 50-mg Tablets

Código ATC: L01EF03 - ABEMACICLIB

State Type of participants Age Ranges

Gender Phases Expected Participants

Results Low level of intervention Rare disease

Geographic coverage Areas of the study Sponsor type

Identifier Protocol Code

Temporary moments of secondary assessment

Temporary moments of secondary assessment

Authorization Start of Trial First patient Halted Restarted

End of Premature end Premature End Trial end Trial end

Eli Lilly Cork Limited Ireland

Monetary support: N/A

not initialized (--/--/----)

not initialized (--/--/----)

not initialized (--/--/----)

ABIRATERONE ACETATE PREDNISONE

Active Principles: N/A

Verzenios 50 mg film-coated tablets Placebo to Match LY2835219 50-mg Tablets

ATC code: L01EF03 - ABEMACICLIB

You might also like